These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 23863411

  • 21. Therapy with pamidronate in children with osteogenesis imperfecta.
    Marginean O, Tamasanu RC, Mang N, Mozos I, Brad GF.
    Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
    [Abstract] [Full Text] [Related]

  • 22. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C.
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [Abstract] [Full Text] [Related]

  • 23. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
    Arikoski P, Silverwood B, Tillmann V, Bishop NJ.
    Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
    [Abstract] [Full Text] [Related]

  • 24. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
    Alharbi M, Pinto G, Finidori G, Souberbielle JC, Guillou F, Gaubicher S, Le Merrer M, Polak M.
    Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235
    [Abstract] [Full Text] [Related]

  • 25. New trends in the treatment of osteogenesis imperfecta type III - own experience.
    Jakubowska-Pietkiewicz E, Chlebna-Sokół D.
    Ortop Traumatol Rehabil; 2008 Jan; 10(6):593-601. PubMed ID: 19153548
    [Abstract] [Full Text] [Related]

  • 26. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T, Turan S, Guran T, Bereket A.
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [Abstract] [Full Text] [Related]

  • 27. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
    Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML.
    Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
    [Abstract] [Full Text] [Related]

  • 28. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H, Vuorimies I, Haukka J, Valta H, Waltimo-Sirén J, Mäkitie O.
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [Abstract] [Full Text] [Related]

  • 29. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.
    Rauch F, Travers R, Glorieux FH.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):511-6. PubMed ID: 16291701
    [Abstract] [Full Text] [Related]

  • 30. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS, Glorieux FH, Rauch F.
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [Abstract] [Full Text] [Related]

  • 31. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E, Magnusson P, Eksborg S, Söderhäll S.
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [Abstract] [Full Text] [Related]

  • 32. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
    Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, Engelbert RH, Sillence DO, Munns CF.
    Horm Res Paediatr; 2013 Dec; 79(6):333-40. PubMed ID: 23735642
    [Abstract] [Full Text] [Related]

  • 33. Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
    Kashii M, Kanayama S, Kitaoka T, Makino T, Kaito T, Iwasaki M, Kubota T, Yamamoto T, Ozono K, Yoshikawa H.
    J Bone Miner Metab; 2019 May; 37(3):545-553. PubMed ID: 30187275
    [Abstract] [Full Text] [Related]

  • 34. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Söderhäll S, Ljunggren Ö, Åström E.
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [Abstract] [Full Text] [Related]

  • 35. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
    Aström E, Jorulf H, Söderhäll S.
    Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
    [Abstract] [Full Text] [Related]

  • 36. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S, Tavakkoli S.
    J Pediatr Endocrinol Metab; 2010 Apr; 23(1-2):73-80. PubMed ID: 20432809
    [Abstract] [Full Text] [Related]

  • 37. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA, Ford L, McClintock C, Peacock M.
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [Abstract] [Full Text] [Related]

  • 38. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P, Palomo T, Montpetit K, Fassier F, Sato A, Glorieux FH, Rauch F.
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [Abstract] [Full Text] [Related]

  • 39. Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta.
    Semler O, Beccard R, Palmisano D, Demant A, Fricke O, Schoenau E, Koerber F.
    Horm Res Paediatr; 2011 Oct; 76(5):321-7. PubMed ID: 21952409
    [Abstract] [Full Text] [Related]

  • 40. Two doses of pamidronate in infants with osteogenesis imperfecta.
    Senthilnathan S, Walker E, Bishop NJ.
    Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.